Barclays Maintains Overweight on GoodRx Holdings, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Stephanie Davis maintains an Overweight rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $9 to $10.
May 20, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Stephanie Davis maintains an Overweight rating on GoodRx Holdings and raises the price target from $9 to $10.
The raised price target and maintained Overweight rating from Barclays is a positive signal for investors, indicating confidence in GoodRx Holdings' future performance. This is likely to have a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100